DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

Pharmaceutics. 2023 Jul 11;15(7):1926. doi: 10.3390/pharmaceutics15071926.

Abstract

The present review aims to explore the potential targets/partners for future targeted radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively, despite receiving a high average tumor radiation dose. Here, we shall discuss the key factors in the cancer genome, especially those related to DNA damage response/repair and maintenance systems for escaping cell death in cancer cells. To overcome the current limitations of TRT effectiveness due to radiation/drug-tolerant cells and tumor heterogeneity, and to make TRT more effective, we propose that a promising strategy would be to target the DNA maintenance factors that are crucial for cancer survival. Considering their cancer-specific DNA damage response/repair ability and dysregulated transcription/epigenetic system, key factors such as PARP, ATM/ATR, amplified/overexpressed transcription factors, and DNA methyltransferases have the potential to be molecular targets for Auger electron therapy; moreover, their inhibition by non-radioactive molecules could be a partnering component for enhancing the therapeutic response of TRT.

Keywords: DNA damage response; DNA repair inhibitor; PARP; auger electron emitters; targeted radionuclide therapy; transcription factor.

Publication types

  • Review

Grants and funding

This research received no external funding.